Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
All news
(page 26)
16 June 2026
Sinopec selected for 2026 low‑carbon case
Chosen among 28 'Finding Zero‑Carbon Factories' cases for 2026; honoured for 16 consecutive years and highlighted for projects, capacity and efficiency measures.
16 June 2026
Mitsubishi Chemical’s DURABIO chosen for Audi Q3 door switch inserts
Selected for single-component door switch panels in the new Audi Q3, offering three textures, mold-in-color piano black and reduced painting, VOCs and CO₂ emissions.
15 June 2026
EIB: Egypt and EU invest €690 million to modernise Egypt's electricity grid
Up to €690m will fund grid upgrades to integrate 22 GW of solar and wind by 2030, cut transmission losses, improve reliability and reinforce Egypt as a regional clean‑energy hub.
15 June 2026
Nobian commissions fully electrified MVR salt plant in Mariager
Fully electrified MVR salt plant starts operation in Mariager, boosting capacity ~60% to up to 1 million tons/yr while cutting energy use and CO₂ emissions.
15 June 2026
Takeda’s oveporexton improved function, cognition and nighttime sleep in narcolepsy type 1
Phase 3 secondary/exploratory endpoints showed benefits across daily functioning, cognitive measures and REM sleep patterns; NDA has Priority Review with a Q3 PDUFA goal date.
15 June 2026
Videberg Kraft selects Rolls‑Royce SMR for three reactors at Värö Peninsula
Detailed planning starts for three modular PWR reactors (470 MW each) expected to produce ~12 TWh/year; supplier choice follows a four-year evaluation of more than 70 options.
News type
Project Updates and Milestones
New Projects and Expansions
Mergers, Acquisitions, and Partnerships
Innovation and Product Development
Operational Changes and Investments
Sustainability and Environmental Initiatives
Financial Performance and Strategy
Executive Appointments and Governance Changes
Regulatory and Compliance Updates
Workforce and Corporate Social Responsibility (CSR)
Crisis and Risk Management
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
15 June 2026
Eastman acquires Jarylec dielectric brand from Arkema
Acquisition covers trademarks, customer list, technical documentation and IP for dielectric fluids used in high‑voltage transformers; production stays in Marl, Germany.
15 June 2026
UPM Adhesive Materials 2025 Climate Review: emissions cuts and value-chain collaboration
58% cut in scope 1–2 emission intensity vs 2015, expanded supplier carbon data, product footprints cover ~94% of label sales, and recycling services support release liner waste recovery.
15 June 2026
Croda’s Avanti Polar Lipids partners with NovoArc to expand lipid offering for pharma research
Adds advanced lipid technologies offering improved stability and enabling new delivery routes for mRNA, protein and peptide therapeutics; initially for research use with scale-up development.
15 June 2026
Stahl acquires Weilburger Graphics packaging coatings business in Brazil
Acquisition adds Weilburger Graphics' Brazil packaging coatings portfolio; production to be insourced in 2026 and local manufacturing capacity expanded; closing pending approvals.
15 June 2026
Statkraft to build Blåfjell Pump into Blåsjø reservoir
Pump will lift water ~60 m into Norway’s largest hydropower reservoir, adding 54 GWh to Ulla‑Førre output; four local contracts awarded totalling NOK 250m.
15 June 2026
LKAB granted environmental permit for expanded Malmberget operations
Court allows continued and expanded mining and processing in Malmberget, including a demo fossil-free sponge iron plant and an apatite processing line for Luleå supply.
15 June 2026
Equinor advances Johan Sverdrup phase 4 subsea development
Appraisal wells confirmed 20–30 million boe in Tonjer and Geitungen; planned subsea tie-back to maintain Johan Sverdrup production with possible start-up in 2029.
15 June 2026
Symrise renews and ups €750m revolving credit facility
Refinanced existing RCF and increased volume to €750m with five-year term, two one-year extension options and a €250m accordion; terms aided by investment-grade ratings.
15 June 2026
OMV Petrom advances Gabare solar-plus-storage into development
Final investment decision for Gabare: ~415 MWp PV with ~600 MWh BESS, EUR 300m investment, first production targeted for 2028.
15 June 2026
Mitsui Chemicals — Developing Dental Materials M&A as a Third Growth Pillar
Acquire Ultradent to build a US dental materials platform, lift L&HC to ¥86bn by FY30 (ROS 17%), and capture whitening growth amid broader specialty-chemicals repositioning.
15 June 2026
Sinopec launches 9,436 km² 3D continuous seismic processing project
Largest continuous 3D seismic processing campaign covers 9,436 km² to support Sichuan Basin exploration, reserve growth and well targeting.
14 June 2026
Lilly: Jaypirca plus venetoclax‑rituximab lowers progression risk 45% in relapsed/refractory CLL/SLL
Phase 3 BRUIN CLL-322 found adding pirtobrutinib to a two‑year venetoclax+rituximab regimen reduced progression or death by 45% versus venetoclax+rituximab alone.
13 June 2026
Lilly reports Phase 1 results for AJ1-11095, a first‑in‑class type II JAK2 inhibitor
Phase 1 data show 70% SVR35 and TSS50 rates, VAF reductions in 21/23 patients, no dose‑limiting toxicities; expansion and further indications planned.
13 June 2026
Johnson & Johnson: TALVEY plus DARZALEX FASPRO shows superior PFS and OS in Phase 3 MonumenTAL‑3
GPRC5D bispecific plus anti‑CD38 combo cut progression risk and delivered 24‑month PFS up to 81% and OS up to 89% in earlier‑line relapsed/refractory multiple myeloma.
13 June 2026
Genmab: Epcoritamab shows high response rates in elderly first‑line DLBCL with mono and R‑mini‑CHOP regimens
Fixed‑duration subcutaneous epcoritamab produced rapid, durable responses and high MRD negativity in elderly newly diagnosed DLBCL patients ineligible for full‑dose anthracycline therapy.
12 June 2026
SunGas ends Beaver Lake bio-methanol project
Planned wood-fiber-to-low-carbon-methanol plant near Alexandria will not proceed, citing slow market uptake, CCS and regulatory/financing uncertainty.
12 June 2026
Roche VENTANA PTEN (SP218) FDA-cleared as PTEN companion diagnostic in prostate cancer
First FDA-cleared IHC companion diagnostic to detect PTEN protein loss and select patients for capivasertib (TRUQAP) plus abiraterone therapy.
12 June 2026
Merck: FDA approves KEYTRUDA and KEYTRUDA QLEX with WELIREG for adjuvant ccRCC
FDA cleared PD‑1 plus HIF‑2α adjuvant regimens after Phase 3 showed 28% lower recurrence risk and 81% vs 74% 24‑month DFS; notable anemia, hypoxia and treatment discontinuations.
12 June 2026
BASF’s Tinosorb S (bemotrizinol) approved by FDA as first new U.S. sunscreen active in 27 years
FDA clears bemotrizinol, a broad‑spectrum, photostable UV filter that enables longer‑lasting, stronger UVA/UVB protection and improved formulation stability.
12 June 2026
Mitsui Chemicals to acquire Ultradent via U.S. holding company
Acquiring Utah-based dental-products maker for $900M; will combine Ultradent with Kulzer, move oral-care HQ to the U.S., and target closing in Sept 2026.
12 June 2026
Chugai files Tecentriq for maintenance therapy after definitive chemoradiotherapy in locally advanced esophageal cancer
Submission seeks approval of an anti‑PD‑L1 agent as maintenance therapy after definitive chemoradiotherapy, supported by SKYSCRAPER‑07 Phase III interim results.
12 June 2026
GSK’s momelotinib gains orphan drug status in US and EU for VEXAS
Orphan designations back development of momelotinib for VEXAS; ATLAS phase II/III underway with design to be shown at EHA 2026.
12 June 2026
Sinopec and Inner Mongolia sign comprehensive strategic cooperation agreement
Regional government and state energy group agree to deepen project-level cooperation, align development plans and expand projects including hydrogen, carbon fiber and coal-chemicals.
11 June 2026
Merck Animal Health to acquire TARGAN
Adds high-speed biodevices including vision-based chick gendering and an ocular vaccine spray; deal expected to close in Q3 2026 pending approvals.
← Previous
Next →